Our Network

About Synthis Therapeutics
Academic Partnerships

Synthis Therapeutics was founded in 2017 based upon the research of its founder, Dori Thomas-Karyat, an expert in the field of immuno-oncology. Dori has strong connections and partnerships with Washington University where she completed her PhD in Immunology. 

 

Synthis Therapeutics is based in NYC at Alexandria LaunchLabs next to NYU Medical Center. Our academic partnership is with NYU through its research institutes and business incubators. Synthis Therapeutics was a part of the Endless Frontier Labs Accelerator Program 2019-2020 and continues to work with NYU presently.

Funding

Synthis Therapeutics is a pre-seed startup with the technology fully owned for its therapeutic platform. Synthis Therapeutics is funded by multiple NCI Phase I SBIR Awards.

Screen Shot 2020-06-02 at 6.17.12 AM.png
Professional Network:
Screen Shot 2020-06-02 at 6.14.51 AM.png
File_Roche_Logo.png
Pfizer_logo.svg.png
1280px-Merck_Logo.svg.png
immunogen-logo2.jpg
abbvie-logo.jpg
bmyslogo.jpg
Screen Shot 2020-06-02 at 6.18.40 AM.png
Screen Shot 2020-06-02 at 6.20.04 AM.png
Screen Shot 2020-06-02 at 6.19.57 AM.png

Key Publications

Natural regulatory T cells are resistant to calcium release-activated calcium (CRAC/ORAI) channel inhibition

          https://www.ncbi.nlm.nih.gov/pubmed/23667148

TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance

        https://www.cell.com/cancer-cell/fulltext/S1535-6108(05)00331-4

TL1A/TNFSF15 directly induces proinflammatory cytokines, including TNFa, from CD3 þ CD161 þ T cells to exacerbate gut inflammation

        https://www.nature.com/articles/mi2012124.pdf?origin=ppub